CEO: Hans Arwidsson
Beskrivning: Eurocine Vaccines is a publicly listed company, using its clinically validated technology Endocine™ to develop a patent protected nasal influenza vaccine for children. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza. The company´s main project, the nasal quadrivalent influenza vaccine Immunose™ FLU, is planned to enter clinical development in the fall of 2016.
The company plans to license the product to partners for further development and commercialization.
For further information about Eurocine Vaccines, please see www.eurocine-vaccines.com.